Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic ... Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa. Show more
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52...
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in...
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1999 | -4.54318181818 | 4.4 | 4.7944 | 4.2 | 50937 | 4.63274292 | CS |
4 | -0.9299 | -18.126705653 | 5.13 | 12.3199 | 4.03 | 1165353 | 6.9379 | CS |
12 | -0.1099 | -2.54988399072 | 4.31 | 12.3199 | 3.54 | 413473 | 6.84949808 | CS |
26 | -1.2359 | -22.7354672553 | 5.436 | 12.3199 | 3.54 | 233504 | 6.52387367 | CS |
52 | -10.7999 | -71.9993333333 | 15 | 17.4 | 3.54 | 138656 | 6.86544612 | CS |
156 | -6.4835 | -60.6864727245 | 10.6836 | 71.52 | 2.7132 | 549355 | 12.8005899 | CS |
260 | -10.5599 | -71.5440379404 | 14.76 | 72.7536 | 2.7132 | 534789 | 20.5992199 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales